Generic weight-loss drug entry in South Africa challenges illicit market

The introduction of generic versions of GLP-1 receptor agonists in South Africa follows patent expirations for blockbuster diabetes and weight-loss medications. It remains uncertain whether lower price points will effectively displace the unregulated black market or facilitate integration into the public health sector.